Morgan Stanley’s Traws Pharma TRAW Stock Holding History

Morgan Stanley’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$395	Sell	468 -3,261	-87%	-$4.49K	﹤0.01%	7730
2026 Q1	$6.82K	Buy	+3,729	New	+$7.01K	﹤0.01%	7058
2025 Q4	–	Sell	-719	Closed	-$1.33K	–	8507
2025 Q3	$1.33K	Hold	719	–	–	﹤0.01%	7367
2025 Q2	$1.06K	Sell	719 -6	-0.8%	-$10	﹤0.01%	7329
2025 Q1	$1.67K	Sell	725 -15,000	-95%	-$78K	﹤0.01%	7206
2024 Q4	$140K	Buy	15,725 +14,996	+2,057%	+$83.5K	﹤0.01%	5924
2024 Q3	$4.29K	Sell	729 -1	-0.1%	-$9	﹤0.01%	6954
2024 Q2	$8.15K	Sell	730 -24	-3%	-$387	﹤0.01%	6736
2024 Q1	$19K	Sell	754 -754	-50%	-$14.5K	﹤0.01%	6506
2023 Q4	$28.1K	Buy	1,508 +704	+88%	+$12K	﹤0.01%	6542
2023 Q3	$14.3K	Hold	804	–	–	﹤0.01%	6593
2023 Q2	$23.7K	Buy	804 +370	+85%	+$9.95K	﹤0.01%	6510
2023 Q1	$7.94K	Hold	434	–	–	﹤0.01%	6949
2022 Q4	$7.01K	Hold	434	–	–	﹤0.01%	7056
2022 Q3	$9K	Sell	434 -200	-32%	-$6.04K	﹤0.01%	7123
2022 Q2	$21K	Sell	634 -44	-6%	-$1.49K	﹤0.01%	6970
2022 Q1	$31K	Buy	678 +26	+4%	+$1.21K	﹤0.01%	6948
2021 Q4	$41K	Sell	652 -1,200	-65%	-$96.5K	﹤0.01%	6910
2021 Q3	$177K	Sell	1,852 -2,419	-57%	-$312K	﹤0.01%	6061
2021 Q2	$740K	Buy	4,271 +3,960	+1,273%	+$896K	﹤0.01%	5262
2021 Q1	$117K	Buy	311 +176	+130%	+$66.4K	﹤0.01%	5929
2020 Q4	$23K	Buy	135 +133	+6,650%	+$15.4K	﹤0.01%	6397
2020 Q3	$0	Hold	2	–	–	﹤0.01%	6845
2020 Q2	$0	Hold	2	–	–	﹤0.01%	6745
2020 Q1	$0	Hold	2	–	–	﹤0.01%	6730
2019 Q4	$0	Hold	2	–	–	﹤0.01%	6786
2019 Q3	$1K	Hold	2	–	–	﹤0.01%	6584
2019 Q2	$2K	Hold	2	–	–	﹤0.01%	6478
2019 Q1	$2K	Hold	2	–	–	﹤0.01%	6475
2018 Q4	$1K	Hold	2	–	–	﹤0.01%	6528
2018 Q3	$5K	Hold	2	–	–	﹤0.01%	6455
2018 Q2	$4K	Hold	2	–	–	﹤0.01%	6483
2018 Q1	$8K	Buy	+2	New	+$14.3K	﹤0.01%	6316
2017 Q2	–	Hold	0	–	-$4K	–	6666
2017 Q1	–	Hold	0	–	–	–	6394
2016 Q4	–	Hold	0	–	–	–	6352
2016 Q3	–	Hold	0	–	–	–	6574
2016 Q2	–	Hold	0	–	–	–	6672
2016 Q1	–	Hold	0	–	–	–	6735
2015 Q4	–	Hold	0	–	–	–	6817
2015 Q3	–	Hold	0	–	–	–	6457
2015 Q2	–	Hold	0	–	–	–	6449
2015 Q1	–	Hold	0	–	–	–	6375
2014 Q4	–	Hold	0	–	–	–	6303
2014 Q3	–	Hold	0	–	–	–	6247
2014 Q2	–	Sell	-1	Closed	-$295K	–	5582
2014 Q1	$183K	Buy	+1	New	+$602K	﹤0.01%	5160
2013 Q4	–	Sell	-1	Closed	-$947K	–	5068
2013 Q3	$975K	Buy	+1	New	+$1.43M	﹤0.01%	3807

Other funds holding TRAW

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Morgan Stanley's TRAW Position: Q2 2026 in Review

Morgan Stanley reduced its Traws Pharma (TRAW) stake by 87% in Q2 2026, selling an estimated $4.49K and leaving 468 shares worth $395. The position accounts for ﹤0.01% of the portfolio, ranked #7730.

Morgan Stanley first reported a position in TRAW in Q3 2013 and has held it in 35 quarters since. The position peaked at $975K in Q3 2013. 21 funds tracked by Wall St. Rank hold TRAW as of Q2 2026.

Morgan Stanley held 468 shares of Traws Pharma worth $395 as of Q2 2026.
Morgan Stanley sold 3,261 Traws Pharma shares in Q2 2026, an estimated $4.49K.
Traws Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7730 holding.
Morgan Stanley first reported a position in Traws Pharma in Q3 2013 and has held it in 35 quarters since.
Morgan Stanley's Traws Pharma position peaked at $975K in Q3 2013.
21 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.